ERBB2 and breast cancer: The hormone receptor-positive (HR+) (ER+ and/or PR+), HER2-negative (HER2−) subtype appears to account for the majority of breast cancers (>50%) and has the best prognosis because of effective targeted hormonal therapies and a more indolent disease phenotype.